CATAPULT GROUP INTERNATIONAL LIMITED (CAT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CAT - CATAPULT GROUP INTERNATIONAL LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Technology Hardware & Equipment
Debt/EBITDA: -1.67
Index: ALL-ORDS

Catapult Group develops and sells wearable sensors to monitor and analyse athletic performance, including fitness and skill levels, injury risks and rehabilitation assistance. It listed on the ASX in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.085

02 Oct
2023

0.015

OPEN

$1.06

1.40%

HIGH

$1.09

67,017

LOW

$1.06

TARGET
$1.525 40.6% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MEB . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CAT: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 3.5 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201720182019202120222023
EPS Basic xxxxxxxxxxxxxxx-19.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx123.4 M
Book Value Per Share xxxxxxxxxxxxxxx53.3
Net Operating Cash Flow xxxxxxxxxxxxxxx4.8 M
Net Profit Margin xxxxxxxxxxxxxxx-37.29 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-33.49 %
Return on Invested Capital xxxxxxxxxxxxxxx-30.45 %
Return on Assets xxxxxxxxxxxxxxx-19.40 %
Return on Equity xxxxxxxxxxxxxxx-33.49 %
Return on Total Capital xxxxxxxxxxxxxxx-31.01 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-8.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202120222023
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx26 M
Total Debt xxxxxxxxxxxxxxx29 M
Goodwill - Gross xxxxxxxxxxxxxxx77 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx24 M
Price To Book Value xxxxxxxxxxxxxxx1.25

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202120222023
Capex xxxxxxxxxxxxxxx36.9 M
Capex % of Sales xxxxxxxxxxxxxxx29.93 %
Cost of Goods Sold xxxxxxxxxxxxxxx143 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx29 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Shaw and Partners

31/05/2023

1

Buy

$1.70

56.68%

Catapult International's FY23 sharply outpaced Shaw and Partners' forecasts, as strong annualised contract value (ACV) growth combined with a big cost beat to place it on track to be free cash flow positive by FY24, a target which now appears to be derisked, advises the broker.

Shaw and Partners considers the company's Tactics and Coaching (T&C/video) opportunity to be a large, low-risk, long-term growth driver and forecasts a compound annual growth rate for ACV and T&C of 12% through to FY33. 

The broker also considers its top-line forecasts to be conservative in the light of recent investment.

Buy rating retained. Target price rises to $1.70 from $1.60.

FORECAST
Shaw and Partners forecasts a full year FY24 dividend of 0.00 cents and EPS of 2.26 cents.
Shaw and Partners forecasts a full year FY25 dividend of 0.00 cents and EPS of 5.87 cents.
Access Stockbroker Research History >

CAT STOCK CHART

FNArena News on CAT

1
Australian Broker Call *Extra* Edition – May 30, 2023

May 30 2023 - Daily Market Reports
2
FNArena Corporate Results Monitor – 29-05-2023

May 29 2023 - Australia
3
Weekly Ratings, Targets, Forecast Changes – 26-05-23

May 29 2023 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Apr 11, 2023

Apr 11 2023 - Daily Market Reports
5
Rudi’s View: CSL, Mineral Resources, Ridley & ReadyTech

Feb 03 2023 - Rudi's View

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
2
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
3
ResMed: Finding A Base?

Aug 15 2023 - Technicals
4
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
5
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
6
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
7
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
8
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest
9
Dr Boreham’s Crucible: Volpara Health Technologies

Apr 26 2023 - Small Caps
10
Dr Boreham’s Crucible: SDI

Mar 16 2023 - Small Caps